AlphAIalphai — Financial news for AI agents
barchart.comAUG 272 min read$ALGN

Are Wall Street Analysts Bullish on Align Technology Stock?

Align Technology (ALGN), a medical device company, has underperformed the broader market and healthcare sector ETF over the past 52 weeks. Analysts expect its adjusted EPS to grow 10.9% YoY by 2026, with a consensus 'Moderate Buy' rating. The mean price target is $207.07, implying a 30.1% upside. Piper Sandler maintained a 'Buy' rating with a $235 target.

Original reporting
barchart.com
Published Aug 27, 2026, 1:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 8:38 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Are Wall Street Analysts Bullish on Align Technology Stock? — source image
Source · barchart.com
Decision brief

The 30-second read

$ALGNBullishMed
01

Why it matters

The raised price target and maintained Buy rating provide a fresh bullish signal, potentially influencing short‑term buying decisions.

02

Market read

Analyst optimism may boost ALGN and related dental‑tech equities, but broader market impact is modest.

03

What to watch

EU antitrust scrutiny and iTero scanner weakness may dampen growth.

Relevance 7/10Novelty 6/10Timing: post-Aug 19 analyst update

Background

Align Technology reported lagging performance due to weak North American demand and competition, while analysts adjusted targets.

Company-level read

Ticker impact

$ALGNBullishMedium confidence
Context

Piper Sandler analyst maintained a Buy rating and raised the price target to $235, indicating bullish sentiment for Align Technology.

Expected impact

Potential price appreciation of 15-20% if targets are met.

Evidence & confidence

The new $235 target represents a ~50% upside from current levels, reflecting improved growth expectations.

Market effects

Sector

Positive outlook may lift other orthodontic and dental device stocks.

Regional

U.S. healthcare sector could see modest gains from renewed investor interest.

Global

Limited to markets where Align operates; minimal global ripple.

Counterpoint

What could challenge this read

Recent demand stagnation and competition could limit upside despite higher targets.

Key entities

  • company
    Align Technology

    Dental device maker known for Invisalign.

  • analyst_firm
    Piper Sandler

    Investment bank providing the Buy rating and $235 price target.

Read at source← All news

Related articles

SEP 1
$ALGNLow

Align Tech adds Quentin Blackford to board

Align Technology (ALGN) added Quentin Blackford, CEO of iRhythm Technologies, to its board, expanding it to 11 members. Blackford brings healthcare and digital innovation experience. Director Andrea L. Saia will retire in September 2026, reducing the board to 10 members.

theglobeandmail.com1 min
AUG 12
$ALGNMed

Align Technology Prevails in China Patent Infringement Action Against Angelalign

Align Technology said a Jinan Intermediate People’s Court issued a first-instance ruling on Aug. 10, 2026 in a China patent case against Angel. The court found Angel’s MasterForce and ATreat systems infringe Align’s CN113693748B patent and ordered Angel to stop use, manufacturing, and sales, awarding RMB 10 million in damages. Angel can appeal to China’s Supreme People’s Court.

antaranews.com4 min
AUG 12
$ALGNMed

Align Technology, Inc.: Align Technology Prevails in China Patent Infringement Action Against Angelalign

Align Technology (Nasdaq: ALGN) said China’s Jinan Intermediate People’s Court ruled in its favor in a patent infringement case against Angelalign’s China subsidiaries. The court found Angel infringed Align’s CN113693748B patent tied to extraction-gap-closure technology, ordering a stop to use and sales in China and awarding RMB 10 million in damages. Angel can appeal.

finanznachrichten.de4 min
AUG 10
$DDDMed

3D Printing Financials: 3D Systems, Prodways, and Align Build on Positive Momentum - 3DPrint.com

3D Systems reported Q2 revenue of $94.6M, flat YoY, with healthcare up 6.8% and aerospace/defense and data center infrastructure each growing over 20%. Adjusted EBITDA loss narrowed to $0.8M. It expects Q3 revenue of $96M to $99M. Prodways posted Q2 revenue of €10.5M (+5% YoY) and plans a €20M buyback. Align Technology reported record Q2 revenue of just over $1.05B (+4.3%), with clear aligner revenue up 8.2% and 2026 revenue growth guidance of 3% to 4%.

3dprint.com6 min
AUG 8
$ALGNMedAI 9/10

Align Technology (ALGN) Q2 2026 Earnings Call Transcript

Align Technology (ALGN) reported Q2 2026 revenue of $1,056.2 million, up 4.3% y/y, driven by record Clear Aligner volumes and higher ASPs. Clear Aligner revenue rose 8.2% to $870.9 million on 691,785 cases. Systems and Services revenue fell 10.8% to $185.3 million. Q3 revenue guidance is $1.00 to $1.02 billion; full-year growth 3% to 4%.

aol.com7 min